NAGE
Niagen Bioscience, Inc.
Key Financials
Net Income
$17.4M
↑ 103.3%
Gross Profit
$83.2M
↑ 35.1%
Revenue
$129.4M
↑ 29.9%
Operating Income
$16.3M
↑ 110.7%
EPS (Diluted)
$0.20
↑ 81.8%
Total Assets
$106.4M
↑ 55.8%
Total Liabilities
$29.9M
↑ 34.7%
Shareholders' Equity
$76.5M
↑ 66.0%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | NAGE |
| Company Name | Niagen Bioscience, Inc. |
| CIK | 1386570 |
| SIC Code | 2833 |
| SIC Description | Medicinal Chemicals & Botanical Products |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 310-388-6706 |